Omega Reports Fourth Quarter and Full Year 2024 Results
Omega Healthcare Investors (NYSE: OHI) reported strong Q4 2024 results with net income of $116 million ($0.41 per share), up from $57 million in Q4 2023. The company completed $340 million in new investments during Q4, including $179 million in real estate acquisitions and $162 million in real estate loans.
Full-year 2024 highlights include net income of $418 million ($1.55 per share), completion of $1.1 billion in new investments, and issuance of 34 million common shares raising $1.2 billion. The company successfully reduced leverage from 5x to below 4x and improved operational metrics with modest improvements in occupancy and coverage.
For 2025, Omega provided Adjusted FFO guidance of $2.90-$2.98 per diluted share. The company maintains a strong balance sheet with $518.3 million in cash and $1.45 billion in undrawn credit facility capacity as of December 31, 2024.
Omega Healthcare Investors (NYSE: OHI) ha riportato risultati solidi per il quarto trimestre del 2024, con un reddito netto di 116 milioni di dollari (0,41 dollari per azione), in aumento rispetto ai 57 milioni di dollari del quarto trimestre del 2023. L'azienda ha completato 340 milioni di dollari in nuovi investimenti durante il quarto trimestre, inclusi 179 milioni di dollari in acquisizioni immobiliari e 162 milioni di dollari in prestiti immobiliari.
I punti salienti dell'anno intero 2024 includono un reddito netto di 418 milioni di dollari (1,55 dollari per azione), il completamento di 1,1 miliardi di dollari in nuovi investimenti e l'emissione di 34 milioni di azioni comuni, che hanno raccolto 1,2 miliardi di dollari. L'azienda ha ridotto con successo la leva finanziaria da 5x a meno di 4x e ha migliorato i parametri operativi con modesti miglioramenti nel tasso di occupazione e nella copertura.
Per il 2025, Omega ha fornito una guida FFO rettificata di 2,90-2,98 dollari per azione diluita. L'azienda mantiene un bilancio solido con 518,3 milioni di dollari in contante e 1,45 miliardi di dollari di capacità di credito non utilizzata al 31 dicembre 2024.
Omega Healthcare Investors (NYSE: OHI) reportó resultados sólidos para el cuarto trimestre de 2024, con un ingreso neto de 116 millones de dólares (0.41 dólares por acción), un aumento desde los 57 millones de dólares en el cuarto trimestre de 2023. La compañía completó 340 millones de dólares en nuevas inversiones durante el cuarto trimestre, incluyendo 179 millones de dólares en adquisiciones inmobiliarias y 162 millones de dólares en préstamos inmobiliarios.
Los puntos destacados del año completo 2024 incluyen un ingreso neto de 418 millones de dólares (1.55 dólares por acción), la finalización de 1.1 mil millones de dólares en nuevas inversiones, y la emisión de 34 millones de acciones comunes que recaudaron 1.2 mil millones de dólares. La compañía logró reducir la deuda de 5x a menos de 4x y mejoró métricas operativas con ligeras mejoras en la ocupación y la cobertura.
Para 2025, Omega proporcionó una guía de FFO ajustado de 2.90-2.98 dólares por acción diluida. La compañía mantiene un balance sólido con 518.3 millones de dólares en efectivo y 1.45 mil millones de dólares en capacidad de crédito no utilizada a partir del 31 de diciembre de 2024.
오메가 헬스케어 인베스터스 (NYSE: OHI)는 2024년 4분기 실적이 강력하다고 보고했으며, 순이익은 1억 1,600만 달러(주당 0.41달러)로, 2023년 4분기의 5,700만 달러에서 증가했습니다. 회사는 4분기 동안 3억 4,000만 달러의 신규 투자를 완료했으며, 이에는 1억 7,900만 달러의 부동산 인수 및 1억 6,200만 달러의 부동산 대출이 포함됩니다.
2024년 전체 하이라이트에는 4억 1,800만 달러(주당 1.55달러)의 순이익, 11억 달러의 신규 투자 완료, 그리고 3,400만 주의 보통주 발행 및 12억 달러 모금이 포함됩니다. 회사는 레버리지를 5배에서 4배 이하로 성공적으로 줄였으며, 점유율 및 커버리지에서 완만한 개선을 통한 운영 지표를 향상시켰습니다.
2025년을 위해 오메가는 조정된 FFO 지침을 주당 2.90-2.98 달러로 제공했습니다. 회사는 2024년 12월 31일 기준으로 5억 1,830만 달러의 현금과 14억 5천만 달러의 미사용 신용 한도를 유지하고 있습니다.
Omega Healthcare Investors (NYSE: OHI) a annoncé de solides résultats pour le quatrième trimestre 2024, avec un revenu net de 116 millions de dollars (0,41 dollar par action), en hausse par rapport à 57 millions de dollars au quatrième trimestre 2023. L'entreprise a réalisé 340 millions de dollars de nouveaux investissements au cours du quatrième trimestre, dont 179 millions de dollars en acquisitions immobilières et 162 millions de dollars en prêts immobiliers.
Les points saillants de l'année complète 2024 comprennent un revenu net de 418 millions de dollars (1,55 dollar par action), l'achèvement de 1,1 milliard de dollars de nouveaux investissements et l'émission de 34 millions d'actions ordinaires ayant levé 1,2 milliard de dollars. L'entreprise a réussi à réduire son effet de levier de 5x à moins de 4x et à améliorer les indicateurs opérationnels avec des améliorations modestes de l'occupation et de la couverture.
Pour 2025, Omega a fourni une prévision FFO ajustée de 2,90-2,98 dollars par action diluée. L'entreprise maintient un bilan solide avec 518,3 millions de dollars de liquidités et 1,45 milliard de dollars de capacité de crédit non utilisée au 31 décembre 2024.
Omega Healthcare Investors (NYSE: OHI) hat starke Ergebnisse für das vierte Quartal 2024 gemeldet, mit einem Nettogewinn von 116 Millionen Dollar (0,41 Dollar pro Aktie), ein Anstieg von 57 Millionen Dollar im vierten Quartal 2023. Das Unternehmen hat im vierten Quartal 340 Millionen Dollar in neue Investitionen getätigt, einschließlich 179 Millionen Dollar in Immobilienakquisitionen und 162 Millionen Dollar in Immobilienkrediten.
Die Highlights des gesamten Jahres 2024 umfassen einen Nettogewinn von 418 Millionen Dollar (1,55 Dollar pro Aktie), den Abschluss von 1,1 Milliarden Dollar in neuen Investitionen und die Emission von 34 Millionen Stammaktien, die 1,2 Milliarden Dollar eingeworben haben. Das Unternehmen hat erfolgreich die Verschuldung von 5-fach auf unter 4-fach reduziert und die operativen Kennzahlen mit moderaten Verbesserungen bei der Belegung und Deckung verbessert.
Für 2025 gab Omega eine angepasste FFO-Prognose von 2,90-2,98 Dollar pro verwässerter Aktie heraus. Das Unternehmen hält eine starke Bilanz mit 518,3 Millionen Dollar in bar und 1,45 Milliarden Dollar an nicht in Anspruch genommenen Kreditkapazitäten zum 31. Dezember 2024.
- Net income increased 104% YoY to $116 million in Q4 2024
- Completed $1.1 billion in new investments during 2024
- Reduced leverage ratio from 5x to below 4x
- Improved occupancy and coverage metrics in Q4
- Strong liquidity position with $518.3M cash and $1.45B undrawn credit
- Significant share dilution with 34 million new shares issued in 2024
- LaVie Care Centers filed for Chapter 11 bankruptcy in June 2024
- $1.7 million impairment charge on two facilities in Q4 2024
Insights
Omega Healthcare's Q4 2024 results reveal a compelling growth story marked by strategic capital deployment and improved operational metrics. The sequential increase in FAD per share while simultaneously reducing leverage demonstrates exceptional capital management efficiency.
Key operational metrics show encouraging trends: occupancy increased to
The company's investment strategy has been particularly noteworthy:
- Completed
$1.1 billion in new investments during 2024 - Achieved attractive yields of
10.0% on Q4 real estate acquisitions - Structured
10.9% weighted-average interest rates on new loans
The 2025 AFFO guidance of
The improved operator coverage metrics and strategic positioning in the healthcare real estate sector suggest Omega is well-positioned to navigate potential regulatory changes while capitalizing on demographic tailwinds in the skilled nursing sector.
The strengthening operator fundamentals represent a important inflection point for Omega's portfolio quality. The improvement in EBITDARM coverage to 1.87x (before management fees) from 1.63x year-over-year signals enhanced operator financial health and reduced risk to rental income streams.
The operator revenue mix demonstrates resilient government payor support:
- Medicaid/Medicare contribution stable at
52.7% - Private/Insurance segment steady at
28.2% - Diversified revenue streams providing operational stability
LaVie's consistent rent payments through bankruptcy proceedings and Maplewood's increased rental contributions to
The robust
Completed
Issued
Providing 2025 Adjusted FFO Guidance
FOURTH QUARTER 2024 AND RECENT HIGHLIGHTS
-
Net income for the quarter of
, or$116 million per common share, compared to$0.41 , or$57 million per common share, for Q4 2023.$0.22 -
Nareit Funds From Operations (“Nareit FFO”) for the quarter of
, or$196 million per common share, on 287 million weighted-average common shares outstanding, compared to$0.68 , or$129 million per common share, on 257 million weighted-average common shares outstanding, for Q4 2023.$0.50 -
Adjusted Funds From Operations (“Adjusted FFO” or “AFFO”) for the quarter of
, or$214 million per common share, compared to$0.74 , or$173 million per common share, for Q4 2023.$0.68 -
Funds Available for Distribution (“FAD”) for the quarter of
, or$202 million per common share, compared to FAD of$0.70 , or$163 million per common share, for Q4 2023.$0.64 -
Completed approximately
in Q4 new investments consisting of$340 million in real estate acquisitions and$179 million in real estate loans.$162 million -
Issued 11 million common shares in Q4 for gross proceeds of
.$438 million -
Completed
in new investments in Q1 2025 to date.$26 million -
Repaid
of senior unsecured notes due January 15, 2025.$400 million -
In January 2025, submitted notification to extend the maturity date of its
unsecured revolving credit facility and its$1.45 billion term loan to October 30, 2025.$50 million
FULL YEAR 2024 HIGHLIGHTS
-
Net income for 2024 of
, or$418 million per common share, compared to$1.55 , or$249 million per common share, in 2023.$1.00 -
Nareit FFO of
, or$734 million per common share, on 270 million weighted-average common shares outstanding, compared to$2.71 , or$591 million per common share, on 250 million weighted-average common shares outstanding, in 2023.$2.36 -
AFFO of
, or$778 million per common share, compared to$2.87 , or$699 million per common share, in 2023.$2.79 -
FAD of
, or$739 million per common share, compared to FAD of$2.73 , or$657 million per common share, in 2023.$2.62 -
Completed
in 2024 new investments, consisting of$1.1 billion in real estate acquisitions, which includes the assumption of a$696 million mortgage loan, and$243 million in real estate loans.$359 million -
Issued 34 million common shares for gross proceeds of
.$1.2 billion -
Repaid
of senior unsecured notes due April 1, 2024.$400 million
Nareit FFO, AFFO and FAD are supplemental non-GAAP financial measures that the Company believes are useful in evaluating the performance of real estate investment trusts (“REITs”). Reconciliations and further information regarding these non-GAAP measures are provided at the end of this press release.
CEO COMMENTS
Taylor Pickett, Omega’s Chief Executive Officer, stated, “In the fourth quarter, we were again able to increase FAD per share sequentially, while continuing to de-lever the balance sheet. 2024 was a strong year for Omega. We were able to accretively invest over
Mr. Pickett continued, “The backdrop continues to be favorable. Operating metrics remain strong, with both occupancy and coverage modestly improving in the quarter. The pipeline remains very active, and we have a cost of capital that should allow us to continue to accretively invest.”
Mr. Pickett concluded, “As often happens, the change of administration has raised questions around the regulatory and reimbursement environment. While it’s too early to know what, if any, changes may occur, the current administration was very supportive of the industry during their last term, and we look forward to working with them to continue to support the aging population within our communities.”
FOURTH QUARTER 2024 RESULTS
Revenues – Revenues for the quarter ended December 31, 2024 totaled
Expenses – Expenses for the quarter ended December 31, 2024 totaled
Other Income and Expense – Other income for the quarter ended December 31, 2024 totaled
Net Income – Net income for the quarter ended December 31, 2024 totaled
2024 ANNUAL RESULTS
Revenues – Revenues for the year ended December 31, 2024 totaled
Expenses – Expenses for the year ended December 31, 2024 totaled
Other Income and Expense – Other income for the year ended December 31, 2024 totaled
Net Income – Net income for the year ended December 31, 2024 totaled
2024 FOURTH QUARTER PORTFOLIO AND RECENT ACTIVITY
Operator Updates:
LaVie – As previously disclosed, LaVie Care Centers, LLC (“LaVie”) filed for Chapter 11 bankruptcy protection in June 2024. Omega committed
Maplewood – In the fourth quarter of 2024, Maplewood Senior Living (“Maplewood”) paid
New Investments:
The following table presents investment activity:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended |
|
Year Ended |
||||||||
Investment Activity ( |
|
December 31, 2024 |
|
December 31, 2024 |
||||||||
|
|
$ Amount |
|
% |
|
$ Amount |
|
% |
||||
Real property (1) |
|
$ |
178,569 |
|
49.2 |
% |
|
$ |
696,110 |
|
60.1 |
% |
Real estate loans receivable |
|
|
161,530 |
|
44.5 |
% |
|
|
359,048 |
|
31.0 |
% |
Total real property and loan investments |
|
|
340,099 |
|
93.7 |
% |
|
|
1,055,158 |
|
91.1 |
% |
Construction-in-progress |
|
|
7,736 |
|
2.2 |
% |
|
|
63,691 |
|
5.5 |
% |
Capital expenditures |
|
|
14,781 |
|
4.1 |
% |
|
|
39,853 |
|
3.4 |
% |
Total capital investments |
|
|
22,517 |
|
6.3 |
% |
|
|
103,544 |
|
8.9 |
% |
Total |
|
$ |
362,616 |
|
100.0 |
% |
|
$ |
1,158,702 |
|
100.0 |
% |
_______________ | |
(1) |
Real property investments for the year ended include the assumption of a |
Asset Sales and Impairments:
Impairments – During the fourth quarter of 2024, the Company recorded a
Assets Held for Sale – As of December 31, 2024, the Company had 12 facilities classified as assets held for sale, totaling
OPERATOR COVERAGE DATA
The following tables present operator revenue mix, census and coverage data based on information provided by the Company’s operators for the indicated periods. The Company has not independently verified this information and is providing this data for informational purposes only.
|
|
|
|
|
|
|
|
Operator Revenue Mix (1) |
|
|
|
Medicare / |
Private / |
||
|
|
Medicaid |
Insurance |
Other |
|||
Three-months ended September 30, 2024 |
|
52.7 |
% |
28.2 |
% |
19.1 |
% |
Three-months ended June 30, 2024 |
|
53.2 |
% |
28.9 |
% |
17.9 |
% |
Three-months ended March 31, 2024 |
|
52.7 |
% |
30.0 |
% |
17.3 |
% |
Three-months ended December 31, 2023 |
|
55.3 |
% |
28.0 |
% |
16.7 |
% |
Three-months ended September 30, 2023 |
|
55.5 |
% |
28.0 |
% |
16.5 |
% |
_______________ | |
(1) |
Excludes all facilities considered non-core and does not include federal stimulus revenue. For non-core definition, see Fourth Quarter 2024 Financial Supplemental posted in the “Quarterly Supplements” section of Omega’s website. |
|
|
|
|
|
|
|
|
|
|
Coverage Data |
|
|
|
|
Before |
After |
|
|
|
Occupancy (2) |
Management |
Management |
|
Operator Census and Coverage (1) |
|
|
Fees (3) |
Fees (4) |
|
Twelve-months ended September 30, 2024 |
|
81.2 |
% |
1.87x |
1.50x |
Twelve-months ended June 30, 2024 |
|
80.9 |
% |
1.85x |
1.49x |
Twelve-months ended March 31, 2024 |
|
80.2 |
% |
1.78x |
1.42x |
Twelve-months ended December 31, 2023 |
|
79.6 |
% |
1.69x |
1.33x |
Twelve-months ended September 30, 2023 |
|
79.1 |
% |
1.63x |
1.28x |
_______________ | |
(1) |
Excludes facilities considered non-core. For information regarding non-core facilities, see the most recent Quarterly Supplement posted on the Company’s website. |
(2) |
Based on available (operating) beds. |
(3) |
Represents EBITDARM of our operators, defined as earnings before interest, taxes, depreciation, amortization, Rent costs and management fees for the applicable period, divided by the total Rent payable to the Company by its operators during such period. “Rent” refers to the total monthly contractual rent and mortgage interest due under the Company’s lease and mortgage agreements over the applicable period. |
(4) |
Represents EBITDAR of our operators, defined as earnings before interest, taxes, depreciation, amortization, and Rent (as defined in footnote 3) expense for the applicable period, divided by the total Rent payable to the Company by its operators during such period. Assumes a management fee of |
FINANCING ACTIVITIES
Dividend Reinvestment and Common Stock Purchase Plan and ATM Program – The following is a summary of the 2024 quarterly Common Stock Purchase Plan and ATM Program through December 31:
|
Dividend Reinvestment and Common Stock Purchase Plan for 2024 |
|||||||||||||
|
(in thousands, except price per share) |
|||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Q1 |
|
Q2 |
|
Q3 |
|
Q4 |
|
Total |
|||||
Number of shares |
|
29 |
|
|
413 |
|
|
2,575 |
|
|
2,061 |
|
|
5,078 |
Average price per share |
$ |
30.44 |
|
$ |
31.52 |
|
$ |
35.13 |
|
$ |
40.57 |
|
$ |
37.02 |
Gross proceeds |
$ |
882 |
|
$ |
13,015 |
|
$ |
90,469 |
|
$ |
83,603 |
|
$ |
187,969 |
|
ATM Program for 2024 |
|||||||||||||
|
(in thousands, except price per share) |
|||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Q1 |
|
Q2 |
|
Q3 |
|
Q4 |
|
Total |
|||||
Number of shares |
|
1,041 |
|
|
7,212 |
|
|
11,630 |
|
|
8,831 |
|
|
28,714 |
Average price per share |
$ |
31.02 |
|
$ |
32.16 |
|
$ |
37.81 |
|
$ |
40.10 |
|
$ |
36.85 |
Gross proceeds |
$ |
32,295 |
|
$ |
231,920 |
|
$ |
439,685 |
|
$ |
354,180 |
|
$ |
1,058,080 |
BALANCE SHEET AND LIQUIDITY
As of December 31, 2024, the Company had
Revolving Facility and Term Loan Extension – In January 2025, the Company provided notification to extend the maturity date of its
DIVIDENDS
On January 29, 2025, the Board of Directors declared a quarterly cash dividend of
2025 GUIDANCE
The Company expects its 2025 Adjusted FFO to be between
The Company’s Adjusted FFO guidance for 2025 includes the annual impact of acquisitions completed in 2024 and year-to-date in 2025, assumes quarterly G&A expense of approximately
The Company's guidance is based on several assumptions including those noted above, which are subject to change and many of which are outside the Company’s control. If actual results vary from these assumptions, the Company's expectations may change. Without limiting the generality of the foregoing, the timing of collection of rental obligations from operators on a cash basis, the timing and completion of acquisitions, divestitures, restructurings and capital and financing transactions may cause actual results to vary materially from our current expectations. There can be no assurance that the Company will achieve its projected results. The Company may, from time to time, update its publicly announced Adjusted FFO guidance, but it is not obligated to do so.
The Company does not provide a reconciliation for its Adjusted FFO guidance to GAAP net income because it is unable to determine meaningful or accurate estimates of reconciling items without unreasonable effort. This is due to the inherent difficulty of forecasting the timing and/or amounts of various items that would impact future net income. This includes, but is not limited to, changes in the provision for credit losses, real estate impairments, acquisition, merger and transition related costs, straight-line write-offs, gain/loss on assets sold, etc. In particular, the Company is unable to predict with reasonable certainty the amount of change in the provision for credit losses in future periods, which is often a significant reconciling adjustment.
ADDITIONAL INFORMATION
Additional information regarding the Company can be found in its Fourth Quarter 2024 Financial Supplemental posted under “Financial Info” in the Investors section of Omega’s website. The information contained on, or that may be accessed through, Omega’s website, including the information contained in the aforementioned supplemental, is not incorporated by any reference into, and is not part of, this document.
CONFERENCE CALL
The Company will be conducting a conference call on Thursday, February 6, 2025, at 10 a.m. Eastern time to review the Company’s 2024 fourth quarter results and current developments. Analysts and investors within the
To listen to the conference call via webcast, log on to www.omegahealthcare.com and click the “Omega Healthcare Investors, Inc. 4Q Earnings Call” hyper-link on the “Investors” page of Omega’s website. Webcast replays of the call will be available on Omega’s website for approximately two weeks following the call. Additionally, a copy of the earnings release will be available in the “Financial Info” section and “SEC Filings” section on the “Investors” page of Omega’s website.
Omega is a REIT that invests in the long-term healthcare industry, primarily in skilled nursing and assisted living facilities. Its portfolio of assets is operated by a diverse group of healthcare companies, predominantly in a triple-net lease structure. The assets span all regions within the
Forward-Looking Statements and Cautionary Language
This press release includes forward-looking statements within the meaning of the federal securities laws. All statements regarding Omega’s or its tenants’, operators’, borrowers’ or managers’ expected future financial condition, results of operations, cash flows, funds from operations, dividends and dividend plans, financing opportunities and plans, capital markets transactions, business strategy, budgets, projected costs, operating metrics, capital expenditures, competitive positions, acquisitions, investment opportunities, dispositions, facility transitions, growth opportunities, expected lease income, continued qualification as a REIT, plans and objectives of management for future operations and statements that include words such as “anticipate,” “if,” “believe,” “plan,” “estimate,” “expect,” “intend,” “may,” “could,” “should,” “will” and other similar expressions are forward-looking statements. These forward-looking statements are inherently uncertain, and actual results may differ from Omega's expectations.
Omega’s actual results may differ materially from those reflected in such forward-looking statements as a result of a variety of factors, including, among other things: (i) uncertainties relating to the business operations of the operators of Omega’s properties, including those relating to reimbursement by third-party payors, regulatory matters, occupancy levels and quality of care, including the management of infectious diseases; (ii) the timing of our operators’ recovery from staffing shortages, increased costs and decreased occupancy resulting from inflation and the long-term impacts of the Novel coronavirus (“COVID-19”) pandemic and the sufficiency of previous government support and current reimbursement rates to offset such costs and the conditions related thereto; (iii) additional regulatory and other changes in the healthcare sector, including recently issued federal minimum staffing requirements for skilled nursing facilities (“SNFs”) that may further exacerbate labor and occupancy challenges for Omega’s operators; (iv) the ability of any of Omega’s operators in bankruptcy to reject unexpired lease obligations, modify the terms of Omega’s mortgages and impede the ability of Omega to collect unpaid rent or interest during the pendency of a bankruptcy proceeding and retain security deposits for the debtor’s obligations, and other costs and uncertainties associated with operator bankruptcies; (v) changes in tax laws and regulations affecting real estate investment trusts (“REITs”), including as the result of any policy changes driven by the current focus on capital providers to the healthcare industry; (vi) Omega’s ability to re-lease, otherwise transition, or sell underperforming assets or assets held for sale on a timely basis and on terms that allow Omega to realize the carrying value of these assets or to redeploy the proceeds therefrom on favorable terms, including due to the potential impact of changes in the SNF and assisted living facility (“ALF”) markets or local real estate conditions; (vii) the availability and cost of capital to Omega; (viii) changes in Omega’s credit ratings and the ratings of its debt securities; (ix) competition in the financing of healthcare facilities; (x) competition in the long-term healthcare industry and shifts in the perception of various types of long-term care facilities, including SNFs and ALFs; (xi) changes in the financial position of Omega’s operators; (xii) the effect of economic, regulatory and market conditions generally, and particularly in the healthcare industry and in jurisdictions where we conduct business, including the
We caution you that the foregoing list of important factors may not contain all the material factors that are important to you. Accordingly, readers should not place undue reliance on those statements. All forward-looking statements are based upon information available to us on the date of this release. We undertake no obligation to publicly update or revise any forward-looking statement as a result of new information, future events or otherwise, except as otherwise required by law.
OMEGA HEALTHCARE INVESTORS, INC. |
||||||||
CONSOLIDATED BALANCE SHEETS |
||||||||
(in thousands, except per share amounts) |
||||||||
|
|
|
|
|
|
|
||
|
|
December 31, |
|
December 31, |
||||
|
|
2024 |
|
2023 |
||||
|
|
(Unaudited) |
|
|
|
|||
ASSETS |
|
|
|
|
|
|
||
Real estate assets |
|
|
|
|
|
|
||
Buildings and improvements |
|
$ |
7,342,497 |
|
|
$ |
6,894,045 |
|
Land |
|
|
996,701 |
|
|
|
870,310 |
|
Furniture and equipment |
|
|
510,106 |
|
|
|
469,654 |
|
Construction in progress |
|
|
210,870 |
|
|
|
138,410 |
|
Total real estate assets |
|
|
9,060,174 |
|
|
|
8,372,419 |
|
Less accumulated depreciation |
|
|
(2,721,016 |
) |
|
|
(2,469,893 |
) |
Real estate assets – net |
|
|
6,339,158 |
|
|
|
5,902,526 |
|
Investments in direct financing leases – net |
|
|
9,453 |
|
|
|
8,716 |
|
Real estate loans receivable – net |
|
|
1,428,298 |
|
|
|
1,212,162 |
|
Investments in unconsolidated joint ventures |
|
|
88,711 |
|
|
|
188,409 |
|
Assets held for sale |
|
|
56,194 |
|
|
|
67,116 |
|
Total real estate investments |
|
|
7,921,814 |
|
|
|
7,378,929 |
|
Non-real estate loans receivable – net |
|
|
332,274 |
|
|
|
275,615 |
|
Total investments |
|
|
8,254,088 |
|
|
|
7,654,544 |
|
|
|
|
|
|
|
|
||
Cash and cash equivalents |
|
|
518,340 |
|
|
|
442,810 |
|
Restricted cash |
|
|
30,395 |
|
|
|
1,920 |
|
Contractual receivables – net |
|
|
12,611 |
|
|
|
11,888 |
|
Other receivables and lease inducements |
|
|
249,317 |
|
|
|
214,657 |
|
Goodwill |
|
|
643,664 |
|
|
|
643,897 |
|
Other assets |
|
|
189,476 |
|
|
|
147,686 |
|
Total assets |
|
$ |
9,897,891 |
|
|
$ |
9,117,402 |
|
|
|
|
|
|
|
|
||
LIABILITIES AND EQUITY |
|
|
|
|
|
|
||
Revolving credit facility |
|
$ |
— |
|
|
$ |
20,397 |
|
Secured borrowings |
|
|
243,310 |
|
|
|
61,963 |
|
Senior notes and other unsecured borrowings – net |
|
|
4,595,549 |
|
|
|
4,984,956 |
|
Accrued expenses and other liabilities |
|
|
328,193 |
|
|
|
287,795 |
|
Total liabilities |
|
|
5,167,052 |
|
|
|
5,355,111 |
|
|
|
|
|
|
|
|
||
Preferred stock |
|
|
— |
|
|
|
— |
|
Common stock |
|
|
27,912 |
|
|
|
24,528 |
|
Additional paid-in capital |
|
|
7,915,873 |
|
|
|
6,671,198 |
|
Cumulative net earnings |
|
|
4,086,907 |
|
|
|
3,680,581 |
|
Cumulative dividends paid |
|
|
(7,516,750 |
) |
|
|
(6,831,061 |
) |
Accumulated other comprehensive income |
|
|
22,731 |
|
|
|
29,338 |
|
Total stockholders’ equity |
|
|
4,536,673 |
|
|
|
3,574,584 |
|
Noncontrolling interest |
|
|
194,166 |
|
|
|
187,707 |
|
Total equity |
|
|
4,730,839 |
|
|
|
3,762,291 |
|
Total liabilities and equity |
|
$ |
9,897,891 |
|
|
$ |
9,117,402 |
|
OMEGA HEALTHCARE INVESTORS, INC. |
||||||||||||||||
CONSOLIDATED STATEMENTS OF OPERATIONS |
||||||||||||||||
Unaudited |
||||||||||||||||
(in thousands, except per share amounts) |
||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
|
|
Three Months Ended |
|
Year Ended |
||||||||||||
|
|
December 31, |
|
December 31, |
||||||||||||
|
|
2024 |
|
2023 |
|
2024 |
|
2023 |
||||||||
Revenues |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Rental income |
|
$ |
230,813 |
|
|
$ |
204,250 |
|
|
$ |
872,192 |
|
|
$ |
811,031 |
|
Real estate tax and ground lease income |
|
|
4,376 |
|
|
|
3,256 |
|
|
|
15,718 |
|
|
|
15,363 |
|
Real estate loans interest income |
|
|
33,482 |
|
|
|
25,492 |
|
|
|
126,800 |
|
|
|
97,766 |
|
Non-real estate loans interest income |
|
|
9,906 |
|
|
|
6,121 |
|
|
|
30,407 |
|
|
|
22,122 |
|
Miscellaneous income |
|
|
741 |
|
|
|
200 |
|
|
|
6,273 |
|
|
|
3,458 |
|
Total revenues |
|
|
279,318 |
|
|
|
239,319 |
|
|
|
1,051,390 |
|
|
|
949,740 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Expenses |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Depreciation and amortization |
|
|
78,612 |
|
|
|
75,674 |
|
|
|
304,648 |
|
|
|
319,682 |
|
General and administrative |
|
|
12,858 |
|
|
|
9,273 |
|
|
|
49,270 |
|
|
|
44,572 |
|
Real estate tax and ground lease expense |
|
|
3,951 |
|
|
|
3,709 |
|
|
|
16,596 |
|
|
|
16,889 |
|
Stock-based compensation expense |
|
|
9,198 |
|
|
|
8,762 |
|
|
|
36,696 |
|
|
|
35,068 |
|
Acquisition, merger and transition related costs |
|
|
795 |
|
|
|
4,158 |
|
|
|
11,615 |
|
|
|
5,341 |
|
Impairment on real estate properties |
|
|
1,737 |
|
|
|
3,951 |
|
|
|
23,831 |
|
|
|
91,943 |
|
(Recovery) provision for credit losses |
|
|
(720 |
) |
|
|
32,913 |
|
|
|
(15,483 |
) |
|
|
44,556 |
|
Interest expense |
|
|
53,794 |
|
|
|
55,724 |
|
|
|
211,319 |
|
|
|
221,832 |
|
Interest – amortization of deferred financing costs |
|
|
1,446 |
|
|
|
3,705 |
|
|
|
10,397 |
|
|
|
13,697 |
|
Total expenses |
|
|
161,671 |
|
|
|
197,869 |
|
|
|
648,889 |
|
|
|
793,580 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Other income (expense) |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Other (expense) income – net |
|
|
(769 |
) |
|
|
11,146 |
|
|
|
6,826 |
|
|
|
20,297 |
|
Loss on debt extinguishment |
|
|
(116 |
) |
|
|
(486 |
) |
|
|
(1,749 |
) |
|
|
(492 |
) |
Gain on assets sold – net |
|
|
1,886 |
|
|
|
9,712 |
|
|
|
13,168 |
|
|
|
79,668 |
|
Total other income |
|
|
1,001 |
|
|
|
20,372 |
|
|
|
18,245 |
|
|
|
99,473 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Income before income tax expense and income (loss) from unconsolidated joint ventures |
|
|
118,648 |
|
|
|
61,822 |
|
|
|
420,746 |
|
|
|
255,633 |
|
Income tax expense |
|
|
(2,981 |
) |
|
|
(4,163 |
) |
|
|
(10,858 |
) |
|
|
(6,255 |
) |
Income (loss) from unconsolidated joint ventures |
|
|
798 |
|
|
|
(1,137 |
) |
|
|
7,916 |
|
|
|
(582 |
) |
Net income |
|
|
116,465 |
|
|
|
56,522 |
|
|
|
417,804 |
|
|
|
248,796 |
|
Net income attributable to noncontrolling interest |
|
|
(3,124 |
) |
|
|
(1,521 |
) |
|
|
(11,478 |
) |
|
|
(6,616 |
) |
Net income available to common stockholders |
|
$ |
113,341 |
|
|
$ |
55,001 |
|
|
$ |
406,326 |
|
|
$ |
242,180 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Earnings per common share available to common stockholders: |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Basic: |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Net income available to common stockholders |
|
$ |
0.41 |
|
|
$ |
0.22 |
|
|
$ |
1.57 |
|
|
$ |
1.01 |
|
Diluted: |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Net income available to common stockholders |
|
$ |
0.41 |
|
|
$ |
0.22 |
|
|
$ |
1.55 |
|
|
$ |
1.00 |
|
Dividends declared per common share |
|
$ |
0.67 |
|
|
$ |
0.67 |
|
|
$ |
2.68 |
|
|
$ |
2.68 |
|
OMEGA HEALTHCARE INVESTORS, INC. |
||||||||||||||||
Nareit FFO, Adjusted FFO and FAD Reconciliation |
||||||||||||||||
Unaudited |
||||||||||||||||
(in thousands, except per share amounts) |
||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
|
|
Three Months Ended |
|
Year Ended |
||||||||||||
|
|
December 31, |
|
December 31, |
||||||||||||
|
|
2024 |
|
2023 |
|
2024 |
|
2023 |
||||||||
Net income (1) |
|
$ |
116,465 |
|
|
$ |
56,522 |
|
|
$ |
417,804 |
|
|
$ |
248,796 |
|
Deduct gain from real estate dispositions |
|
|
(1,886 |
) |
|
|
(9,712 |
) |
|
|
(13,168 |
) |
|
|
(79,668 |
) |
Deduct gain from real estate dispositions of unconsolidated joint ventures |
|
|
— |
|
|
|
— |
|
|
|
(6,260 |
) |
|
|
— |
|
Sub-total |
|
|
114,579 |
|
|
|
46,810 |
|
|
|
398,376 |
|
|
|
169,128 |
|
Elimination of non-cash items included in net income: |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Depreciation and amortization |
|
|
78,612 |
|
|
|
75,674 |
|
|
|
304,648 |
|
|
|
319,682 |
|
Depreciation - unconsolidated joint ventures |
|
|
673 |
|
|
|
2,482 |
|
|
|
7,057 |
|
|
|
10,423 |
|
Add back provision for impairments on real estate properties |
|
|
1,737 |
|
|
|
3,951 |
|
|
|
23,831 |
|
|
|
91,943 |
|
Nareit funds from operations (“Nareit FFO”) |
|
$ |
195,601 |
|
|
$ |
128,917 |
|
|
$ |
733,912 |
|
|
$ |
591,176 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Weighted-average common shares outstanding, basic |
|
|
274,316 |
|
|
|
245,751 |
|
|
|
258,118 |
|
|
|
240,493 |
|
Restricted stock and PRSUs |
|
|
5,230 |
|
|
|
3,589 |
|
|
|
4,664 |
|
|
|
2,923 |
|
Omega OP Units |
|
|
7,900 |
|
|
|
7,219 |
|
|
|
7,668 |
|
|
|
7,035 |
|
Weighted-average common shares outstanding, diluted |
|
|
287,446 |
|
|
|
256,559 |
|
|
|
270,450 |
|
|
|
250,451 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Nareit funds from operations available per share |
|
$ |
0.68 |
|
|
$ |
0.50 |
|
|
$ |
2.71 |
|
|
$ |
2.36 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Adjustments to calculate adjusted funds from operations |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Nareit FFO |
|
$ |
195,601 |
|
|
$ |
128,917 |
|
|
$ |
733,912 |
|
|
$ |
591,176 |
|
Add back: |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Stock-based compensation expense |
|
|
9,198 |
|
|
|
8,762 |
|
|
|
36,696 |
|
|
|
35,068 |
|
Non-recurring expense |
|
|
5,303 |
|
|
|
384 |
|
|
|
8,619 |
|
|
|
2,277 |
|
Uncollectible accounts receivable (2) |
|
|
3,038 |
|
|
|
— |
|
|
|
4,174 |
|
|
|
20,633 |
|
Acquisition, merger and transition related costs |
|
|
795 |
|
|
|
4,158 |
|
|
|
11,615 |
|
|
|
5,341 |
|
Non-recognized cash interest |
|
|
716 |
|
|
|
207 |
|
|
|
1,630 |
|
|
|
6,378 |
|
Non-cash provision (recovery) for credit losses |
|
|
457 |
|
|
|
34,082 |
|
|
|
(10,771 |
) |
|
|
51,966 |
|
Loss on debt extinguishment |
|
|
116 |
|
|
|
486 |
|
|
|
1,749 |
|
|
|
492 |
|
Add back unconsolidated JV related non-recurring loss |
|
|
— |
|
|
|
1,054 |
|
|
|
— |
|
|
|
2,710 |
|
Deduct: |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Non-recurring revenue |
|
|
(1,244 |
) |
|
|
(4,587 |
) |
|
|
(9,487 |
) |
|
|
(17,368 |
) |
Adjusted funds from operations (“AFFO”) (1)(3) |
|
$ |
213,980 |
|
|
$ |
173,463 |
|
|
$ |
778,137 |
|
|
$ |
698,673 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Adjustments to calculate funds available for distribution |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Non-cash expense(4) |
|
$ |
3,497 |
|
|
$ |
2,676 |
|
|
$ |
12,777 |
|
|
$ |
9,581 |
|
Capitalized interest |
|
|
(2,103 |
) |
|
|
(1,324 |
) |
|
|
(7,312 |
) |
|
|
(4,340 |
) |
Non-cash revenue |
|
|
(13,647 |
) |
|
|
(11,403 |
) |
|
|
(44,954 |
) |
|
|
(47,011 |
) |
Funds available for distribution (“FAD”) (1)(3) |
|
$ |
201,727 |
|
|
$ |
163,412 |
|
|
$ |
738,648 |
|
|
$ |
656,903 |
|
_______________ | |
(1) |
The three and year ended December 31, 2024 include the application of |
(2) |
The year ended December 31, 2023 includes a |
(3) |
Adjusted funds from operations per share and funds available for distribution per share can be calculated using weighted-average common shares outstanding, diluted, as shown above. |
(4) |
For the year ended December 31, 2024, Non-cash expense is not adjusted to include |
Nareit Funds From Operations (“Nareit FFO”), Adjusted FFO and Funds Available for Distribution (“FAD”) are non-GAAP financial measures. As used in this press release, GAAP refers to generally accepted accounting principles in
The Company calculates and reports Nareit FFO in accordance with the definition and interpretive guidelines issued by the National Association of Real Estate Investment Trusts (“Nareit”), and consequently, Nareit FFO is defined as net income (computed in accordance with GAAP), adjusted for the effects of asset dispositions and certain non-cash items, primarily depreciation and amortization and impairments on real estate assets, and after adjustments for unconsolidated partnerships and joint ventures and changes in the fair value of warrants. Adjustments for unconsolidated partnerships and joint ventures will be calculated to reflect funds from operations on the same basis. Revenue recognized based on the application of security deposits and letters of credit or based on the ability to offset against other financial instruments is included within Nareit FFO. The Company believes that Nareit FFO, Adjusted FFO and FAD are important supplemental measures of its operating performance. Because the historical cost accounting convention used for real estate assets requires depreciation (except on land), such accounting presentation implies that the value of real estate assets diminishes predictably over time, while real estate values instead have historically risen or fallen with market conditions. The term funds from operations was designed by the real estate industry to address this issue. Funds from operations described herein is not necessarily comparable to funds from operations of other real estate investment trusts, or REITs, that do not use the same definition or implementation guidelines or interpret the standards differently from the Company.
Adjusted FFO is calculated as Nareit FFO excluding the impact of non-cash stock-based compensation and certain revenue and expense items (e.g., acquisition, merger and transition related costs, write-off of straight-line accounts receivable, recoveries and provisions for credit losses (excluding certain cash recoveries on impaired loans), cash interest received but not included in revenue, non-recognized cash interest, severance, legal reserve expenses, etc.). FAD is calculated as Adjusted FFO less non-cash expense, such as the amortization of deferred financing costs, and non-cash revenue, such as straight-line rent. FAD includes the non-cash amortization of premiums associated with the fair value of debt assumed in acquisitions. The Company believes these measures provide an enhanced measure of the operating performance of the Company’s core portfolio as a REIT. The Company’s computation of Adjusted FFO and FAD may not be comparable to the Nareit definition of funds from operations or to similar measures reported by other REITs, but the Company believes that they are appropriate measures for this Company.
The Company uses these non-GAAP measures among the criteria to measure the operating performance of its business. The Company also uses FAD among the performance metrics for performance-based compensation of officers. The Company further believes that by excluding the effect of depreciation, amortization, impairments on real estate assets and gains or losses from sales of real estate, all of which are based on historical costs, and which may be of limited relevance in evaluating current performance, funds from operations can facilitate comparisons of operating performance between periods. The Company offers these measures to assist the users of its financial statements in analyzing its operating performance. These non-GAAP measures are not measures of financial performance under GAAP and should not be considered as measures of liquidity or cash flow, alternatives to net income or indicators of any other performance measure determined in accordance with GAAP. Investors and potential investors in the Company’s securities should not rely on these non-GAAP measures as substitutes for any GAAP measure, including net income.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250205797216/en/
Andrew Dorsey, VP, Corporate Strategy & Investor Relations
or
David Griffin, Director, Corporate Strategy & Investor Relations at (410) 427-1705
Source: Omega Healthcare Investors, Inc.
FAQ
What was Omega Healthcare's (OHI) net income for Q4 2024?
How much did OHI invest in new acquisitions during 2024?
What is Omega's (OHI) FFO guidance for 2025?
How much equity did OHI raise in 2024?